Abeona Therapeutics Inc.
ABEO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | -0.00 | -1.13 | 0.10 |
| FCF Yield | -8.28% | -7.27% | -8.36% | -7.51% |
| EV / EBITDA | -12.26 | 1.26 | -23.98 | -30.71 |
| Quality | ||||
| ROIC | -2.79% | -9.16% | -21.88% | -16.82% |
| Gross Margin | 0.00% | 75.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 4.11 | -0.17 | 1.53 | 1.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -51.78% | -51.78% | -100.00% | -100.00% |
| Free Cash Flow Growth | -9.32% | -9.50% | -15.37% | -35.82% |
| Safety | ||||
| Net Debt / EBITDA | 3.17 | -1.11 | -0.79 | 0.04 |
| Interest Coverage | -26.66 | -23.82 | -19.77 | -15.41 |
| Efficiency | ||||
| Inventory Turnover | 0.10 | 0.04 | 0.00 | 0.00 |
| Cash Conversion Cycle | -198.63 | -3,819.15 | -554.13 | 31.09 |